Matinas Biopharma Holdings, Inc. (MTNB) Social Stream
Matinas BioPharma Holdings Inc (MTNB) Price Targets From Analysts
Use the tables below to see what analysts covering Matinas BioPharma Holdings Inc think about its future price and what recommendations they have for investors and traders.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
Over the past 19 months, MTNB's average price target has gone down $0.71.
Over the past 120 days, MTNB's average upside potential has been 246.92%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
MTNB Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- In terms of how Matinas BioPharma Holdings Inc fares relative to all US stocks, note that its average analyst price target is greater than 3.47% of that group.
- In the context of all US stocks, Matinas BioPharma Holdings Inc's upside potential (average analyst target price relative to current price) is greater than 356.31% of them.
- In terms of how Matinas BioPharma Holdings Inc fares relative to Pharmaceutical Products stocks, note that its number of analysts covering the stock is higher than 63.39% of that group.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, Matinas BioPharma Holdings Inc's variance in analysts' estimates is lower than -39.44% of them.
In the Pharmaceutical Products industry, MTEM, MRUS, and MRSN are the three stocks most similar to Matinas BioPharma Holdings Inc regarding the price target and analyst recommendation information presented here.
Is MTNB a Buy, Hold or Sell? See the POWR Ratings now!